{"schema_version":"1","generated_at":"2026-11-08T19:12:02.384Z","data_as_of":null,"url":"https://www.findmykol.com/kol/kara-schenk","json_url":"https://www.findmykol.com/kol/kara-schenk/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"kara-schenk","name":"Kara Schenk","credential":"MD","specialty":"Medical Oncology","specialty_raw":"Medical Oncology","therapeutic_area":"Oncology","therapeutic_areas":["Oncology"],"city":"Bozeman","state":"MT","region":{"label":"West","url":"https://www.findmykol.com/region/west"}},"identifiers":{"npi":"1588904346","orcid":"0000-0001-5147-8301","openalex":"A5009470957"},"summary":"Kara Schenk is an Oncology physician. OpenAlex indexes 11 publications with 267 citations (h-index 8).","overview":null,"focus":{"indications":[],"research_topics":["Oncology"]},"scholarship":{"works_count":11,"cited_by_count":267,"h_index":8,"latest_activity_year":2025,"source":"works"},"payments":{"company_count":25,"program_years":{"first":2021,"last":null},"rows_total":42,"shown":3,"withheld":39,"rows":[{"payer":"Pfizer","program_year":2025,"amount_usd":222274.94,"payment_count":25,"source_url":"https://openpaymentsdata.cms.gov/search?query=1588904346"},{"payer":"BioNTech SE","program_year":2025,"amount_usd":22767,"payment_count":4,"source_url":"https://openpaymentsdata.cms.gov/search?query=1588904346"},{"payer":"Stemline Therapeutics Inc.","program_year":2025,"amount_usd":2505.97,"payment_count":2,"source_url":"https://openpaymentsdata.cms.gov/search?query=1588904346"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1588904346","source":"payments"},"prescribing":{"data_year":2024,"areas_total":8,"areas_shown":3,"areas":[{"area":"Cancer & immunology","share_pct":52.6,"classes_total":3,"classes":[{"class":"Aromatase Inhibitor","setting":"prescribed","share_pct":35.9,"drugs":[{"name":"Anastrozole","share_pct":71.8},{"name":"Letrozole","share_pct":28.2}],"max_beneficiaries":29},{"class":"Kinase inhibitor","setting":"prescribed","share_pct":11.1,"drugs":[{"name":"Verzenio","share_pct":58.8},{"name":"Ibrance","share_pct":41.2}],"max_beneficiaries":null}]},{"area":"Metabolism & gastrointestinal","share_pct":10.8,"classes_total":2,"classes":[{"class":"Corticosteroid","setting":"prescribed","share_pct":6.5,"drugs":[{"name":"Prednisone","share_pct":100}],"max_beneficiaries":11},{"class":"Serotonin-3 Receptor Antagonist","setting":"prescribed","share_pct":4.2,"drugs":[{"name":"Ondansetron Odt","share_pct":100}],"max_beneficiaries":11}]},{"area":"Nervous system","share_pct":10.5,"classes_total":1,"classes":[{"class":"Phenothiazine","setting":"prescribed","share_pct":10.5,"drugs":[{"name":"Prochlorperazine Maleate","share_pct":100}],"max_beneficiaries":23}]}],"care_setting":{"dominant":"facility","data_year":2024,"office_pct":0,"facility_pct":100},"source":"medicare"},"publications":{"total":11,"shown":5,"withheld":6,"matched_by":"OpenAlex author record","recent":[{"title":"Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous Cancers","year":2024,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.23.01497","status":"verified"},{"title":"695 Phase 2 study of nivolumab and ipilimumab in combination with sirolimus and prednisone in kidney transplant recipients with selected unresectable or metastatic cutaneous cancers","year":2024,"journal":"Regular and Young Investigator Award Abstracts","source_url":"https://doi.org/10.1136/jitc-2024-sitc2024.0695","status":"verified"},{"title":"Impact of a trainee-led initiative to address PCP prophylaxis barriers.","year":2024,"journal":"JCO Oncology Practice","source_url":"https://doi.org/10.1200/op.2024.20.10_suppl.319","status":"verified"},{"title":"Trainee-led quality improvement (QI) project examining PCP prophylaxis in patients on chronic, high-dose corticosteroids.","year":2024,"journal":"Journal of Clinical Oncology","source_url":"https://doi.org/10.1200/jco.2024.42.16_suppl.e23211","status":"verified"},{"title":"Immune microenvironment of basal cell carcinoma and tumor regression following combined PD-1/LAG-3 blockade","year":2023,"journal":"Journal for ImmunoTherapy of Cancer","source_url":"https://doi.org/10.1136/jitc-2023-007463","status":"verified"}],"source":"works"},"contact":{"address_1":"931 HIGHLAND BLVD STE 3130","city":"Bozeman","state":"MT","zip":"597156914","phone":"406-414-3130","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1588904346","source":"identity"},"similar":[{"name":"Carl June","slug":"carl-june","institution":"University of Pennsylvania","specialty":"Medical Oncology","url":"https://www.findmykol.com/kol/carl-june","json_url":"https://www.findmykol.com/kol/carl-june/profile.json"},{"name":"Rainer Storb","slug":"rainer-storb","institution":"University of Washington","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/rainer-storb","json_url":"https://www.findmykol.com/kol/rainer-storb/profile.json"},{"name":"Christina Fitzmaurice","slug":"christina-fitzmaurice","specialty":"Hematology / Oncology","url":"https://www.findmykol.com/kol/christina-fitzmaurice","json_url":"https://www.findmykol.com/kol/christina-fitzmaurice/profile.json"},{"name":"Beth Karlan","slug":"beth-karlan","institution":"University of California, Los Angeles","specialty":"Gynecologic Oncology","url":"https://www.findmykol.com/kol/beth-karlan","json_url":"https://www.findmykol.com/kol/beth-karlan/profile.json"}],"coverage":{"note":"A basic directory record. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["funding","congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":39,"publications":6}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2025-04-09","provider_certified":"2025-04-09","collected_at":"2026-11-06T00:00:00.000Z"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024}},"methodology_url":"https://www.findmykol.com/about#methodology"}